MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Oragenics Cash Conversion Cycle 2011-2026 | OGEN
Annual Cash Conversion Cycle Oragenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | -40.7 | -37.8 | 64.4 | -112 | -56.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64.4 | -112 | -36.5 |
Quarterly Cash Conversion Cycle Oragenics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.67 | 6.46 | 7.09 | 4.69 | 17 | 13.5 | 23.2 | 35.1 | 34.7 | 14.8 | 24.1 | 24.8 | 19.5 | 21.3 | 24.1 | 24.3 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.1 | 4.69 | 18.8 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Exelixis
EXEL
|
-8.32 | $ 48.43 | 9.03 % | $ 13.2 B | USA |
 |
Fortress Biotech
FBIO
|
-74.9 | $ 2.56 | 3.96 % | $ 71.4 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Galapagos NV
GLPG
|
67.1 | $ 28.78 | 1.36 % | $ 2.69 B |  Belgium |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.41 | 1.69 % | $ 6.83 B |  Spain |
 |
Ionis Pharmaceuticals
IONS
|
-556 | $ 76.96 | 2.27 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
163 | $ 8.3 | 1.1 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
-46.6 | $ 86.14 | 4.15 % | $ 7.28 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 229.83 | -1.06 % | $ 4.2 B | USA |
 |
INmune Bio
INMB
|
19.9 K | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 41.84 | 4.26 % | $ 3.6 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
257 | $ 22.32 | -0.13 % | $ 3.7 B | USA |
 |
MannKind Corporation
MNKD
|
349 | $ 3.68 | 28.5 % | $ 1.12 B | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 23.86 | 1.88 % | $ 3.04 B | USA |
 |
Puma Biotechnology
PBYI
|
80 | $ 7.5 | 2.04 % | $ 375 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |